December 11th, 2pm – 3:30 PM CET
 |
 |
This webinar updated EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access mechanisms.
Featuring: (in order of appearance)
 |
 |
|
| Jeremy Haigh, European Chief Operating Officer, Research & Development Amgen Ltd. |
James Anderson, Director of EU Industry & External Partnerships, GSK |
|
 |
 |
|
| Karin Van Baelen, Head Global Regulatory Affairs Janssen, Pharmaceutical Companies of Johnson and Johnson |
Magda Chlebus, Director Science Policy EFPIA |
The topics of discussion are:
- Medicines Adaptive Pathways to Patients, their benefits for companies, patients, regulators and payers
- Opportunities and barriers to implementing MAPPs
- The status of activities which implement or support implementation of MAPPs (EMA, HTA bodies, Innovative Medicines Initiatives, Newdigs, etc)
| Programme: 90 Minutes | |
| What are MAPPs? | Jeremy Haigh |
| Initiatives supporting adaptive licensing and access | James Anderson Overview of EMA Pilot and NewDigs Karin Van Baelen Overview of the US initiative Breakthrough Designation |
| Collaborative initiatives to progress and enable MAPPs implementation | Magda Chlebus Overview of IMI2 activities and plans |
| Q&A until End | |
